Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

201
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
201

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In silico study of the pharmacokinetics and human and environmental toxicological analysis of cannabidiol.

Brazilian journal of biology = Revista brasleira de biologia·2025
Same author

Acute cannabidiol treatment reverses behavioral impairments induced by embryonic valproic acid exposure in male mice.

Pharmacology, biochemistry, and behavior·2024
Same author

Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.

Neuropharmacology·2021
Same author

Does Parkinson's disease interfere with electromyographic fatigue of masticatory muscles?

Archives italiennes de biologie·2020
Same author

Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms.

Journal of chemical neuroanatomy·2019
Same author

Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.

Psychopharmacology·2019

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms
05:15

Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms

Published on: January 10, 2025

701

Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.

R Ponciano1, J E C Hallak2, J A Crippa2

  • 1Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Neurotoxicity Research
|December 19, 2024
PubMed
Summary

Cannabigerol (CBG) reduced antipsychotic-induced movements in mice, showing potential for treating tardive dyskinesia. However, it did not reverse existing motor effects or alter key biological markers, indicating further research is needed.

Keywords:
FosBMicrogliaPhytocannabinoidTardive dyskinesiaTypical antipsychotic

More Related Videos

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

12.6K
Hyponeophagia: A Measure of Anxiety in the Mouse
05:52

Hyponeophagia: A Measure of Anxiety in the Mouse

Published on: May 17, 2011

21.9K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms
05:15

Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms

Published on: January 10, 2025

701
Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

12.6K
Hyponeophagia: A Measure of Anxiety in the Mouse
05:52

Hyponeophagia: A Measure of Anxiety in the Mouse

Published on: May 17, 2011

21.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Chronic typical antipsychotic use causes motor side effects like tardive dyskinesia (TD).
  • TD is characterized by involuntary movements and may involve D2 receptor hypersensitivity, inflammation, and oxidative stress.
  • Current TD treatments have limited efficacy and significant side effects.

Purpose of the Study:

  • To investigate the potential antidyskinetic effects of cannabigerol (CBG) in a mouse model of tardive dyskinesia.
  • To evaluate if CBG can prevent, ameliorate, or reverse haloperidol-induced vacuous chewing movements.
  • To assess CBG's impact on motor activity and specific neurobiological markers.

Main Methods:

  • Mice received haloperidol to induce vacuous chewing movements.
  • Mice were treated with cannabigerol (CBG) at doses of 3 and 10 mg/kg.
  • Evaluated effects on vacuous chewing, motor activity, FosB expression, and microglia morphology.

Main Results:

  • Cannabigerol (CBG) significantly reduced haloperidol-induced vacuous chewing movements.
  • CBG did not impair normal motor activity or exacerbate haloperidol-induced hypokinesia.
  • No significant reversal of existing motor effects was observed; FosB expression and microglia morphology remained unchanged.

Conclusions:

  • Cannabigerol (CBG) demonstrates preventive and ameliorative effects against antipsychotic-induced dyskinetic movements.
  • Further research is warranted to explore CBG's therapeutic potential for tardive dyskinesia.
  • CBG's mechanism of action in TD requires further investigation, as it did not impact FosB or microglia markers in this study.